Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This recommendation is based on findings from the phase III JAVELIN Renal 101 study involving 886 patients, which demonstrated significant improvements in median […]

read more

European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of pembrolizumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first combination of immunotherapy (pembrolizumab) with a tyrosine kinase inhibitor (axitinib) to receive a […]

read more

Tivozanib expected to be included in European clinical practice guidelines for advanced kidney cancer

Tivozanib is expected to be included as a first-line treatment recommendation for advanced renal cell carcinoma (RCC) in new proposed European guidelines. An outline of the new proposed European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced RCC were presented at the annual ESMO 2018 Congress in Munich, Germany last week. The presentation […]

read more

Open letter calling on Government to prioritise interests of cancer patients in Brexit negotiations

Kidney Cancer Support Network have come together with 18 other cancer charities to put our names to an open letter to Government. We want Government to prioritise seeking continued alignment with the EU drug licensing process and Clinical Trials Regulation after Brexit. It is hoped this letter will be published in the national press in […]

read more

Majority of recently-approved cancer treatments lack survival benefits

A study published in the British Medical Journal (BMJ) states that two thirds of the 48 cancer medicines approved by the European Medicines Agency (EMA) to treat 68 cancers between 2009-2013, came to the market “without clear evidence they could improve survival”.  The study by researchers from King’s College London and the London School of Economics (LSE) […]

read more

Tivozanib given the green light by European regulators for first-line treatment of advanced kidney cancer

Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), has been recommended for approval by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as a first-line treatment for advanced renal cell carcinoma (RCC). The drug was also recommended for second-line treatment of adult patients with advanced […]

read more
Showing all 7 results
  TOP